50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Veracyte stock downgraded by Goldman Sachs, target reduced amid slowing growth

EditorAhmed Abdulazez Abdulkadir
Published 12/05/2024, 07:12 PM
VCYT
-

On Thursday, Goldman Sachs adjusted its stance on Veracyte, Inc (NASDAQ:VCYT), shifting the rating from Buy to Neutral and slightly decreasing the price target to $37 from the previous $38. The firm noted that the stock has outperformed within the Diagnostics sector, highlighting its impressive year-to-date gain of over 60% compared to the S&P 500's increase of approximately 28.5%.

The downgrade comes after observing the average return in the Diagnostic coverage area, which has seen a decline of 15% since November 18, 2021. The firm pointed out the contraction in the next twelve months (NTM) enterprise value to sales (EV/Sales) multiple, which has fallen from 8.7 times to 4.4 times. This shift reflects a cooling of the post-Covid enthusiasm in the Diagnostics space, positioning Veracyte as a relative outperformer.

Veracyte's strong performance is attributed to its consistent top-line growth, which has led to a steady trend of surpassing expectations and raising forecasts over the past two years. This success is particularly notable given that Veracyte is one of the few profitable companies in the Diagnostics industry.

Despite the company's solid track record and potential for continued growth, Goldman Sachs anticipates a possible deceleration in Afrima growth in 2025 due to high market penetration levels. Nevertheless, Decipher Prostate is expected to remain a significant contributor to the company's revenue in the coming year.

The analyst also mentioned several of Veracyte's pipeline projects, including minimal residual disease (MRD), expansion in European in vitro diagnostics (IVU), and the Percepta nasal swab. However, these projects are anticipated to be a few years away from making a substantial impact on the company's revenue streams.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.